Venofer®
Composition
Active substance: Iron in the form of saccharated ferric oxide
One ampoule of 5 mL contains 100 mg iron (Iron sucrose).
Iron deficiency in patients in whom oral iron therapy is insufficiently effective or not feasible, such as:
Venofer must only be administered slowly intravenously.
Venofer must NOT be administered subcutaneously or intramuscularly.
The total cumulative dose of Venofer, corresponding to the total iron deficit (mg), is determined by the haemoglobin value (Hb) and the body weight (BW).
Adults: 5-10 mL Venofer (100-200 mg iron) one to three times weekly
Pain, extravasation, irritation, reaction, discolouration, haematoma, itching at the injection/infusion site.
There are insufficient data from the use of iron sucrose in pregnant women in the first trimester. Data from the use of Venofer® in pregnant women in the second and third trimesters revealed no safety concerns for the mother or the newborn.
Limited data are available on the excretion of iron in human milk after intravenous administration of iron sucrose. Therefore, a risk-benefit assessment must be carried out.
For more information, consult your doctor or your pharmacist.